Drug Profile
Huperzine A - Neuro-Hitech/Xel
Alternative Names: HupA transdermal; Qian-ceng-ta transdermal; XEL 001HG; XEL 001HPLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Guangzhou Xiangxue Pharmaceuticals; Neuro-Hitech; Xel Pharmaceuticals
- Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in China (Transdermal, Patch)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Topical, Gel)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Transdermal, Patch)